Open access
Open access
Powered by Google Translator Translator

Oncology – Lung

NICE Updated Guideline | Diagnosis and management of lung cancer

4 Aug, 2023 | 12:05h | UTC

Lung cancer: diagnosis and management – National Institute for Health and Care Excellence

 


ASCO Guideline Update | Management of Stage III Non–Small-Cell Lung Cancer

4 Aug, 2023 | 12:03h | UTC

Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update – Journal of Clinical Oncology

Commentary: Rapid Guideline Update Offers Key Evidence-Based Recommendations for Stage III NSCLC Management – ASCO Daily News

 


RCT | Lazertinib offers 20.6-month of median PFS in EGFR-mutated NSCLC vs 9.7 months with gefitinib

2 Aug, 2023 | 13:55h | UTC

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301 – Journal of Clinical Medicine

 


Phase 2 Trial | The addition of immunotherapy to stereotactic ablative radiotherapy may enhance EFS in early-stage NSCLC

25 Jul, 2023 | 13:36h | UTC

Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial – The Lancet (link to abstract – $ for full-text)

 


Systematic Review | Platinum doublet therapy outperforms non-platinum for advanced NSCLC, performance status 2 patients

20 Jul, 2023 | 10:56h | UTC

Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status – Cochrane Library

Summary: Best therapy for people with advanced non-small cell lung cancer who have not been treated without a targetable mutation and moderately impaired performance status – Cochrane Library

 


RCT | Atezolizumab in platinum-ineligible NSCLC elevates median survival to 10.3 months vs. 9.2 months with chemotherapy

10 Jul, 2023 | 13:33h | UTC

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study – The Lancet (link to abstract – $ for full-text)

News Release: Immunotherapy for ‘difficult to treat’ lung cancer patients improves long-term survival – University College London

 


RCT | Perioperative nivolumab plus chemotherapy increases pathological response vs. chemotherapy alone in stage III NSCLC

10 Jul, 2023 | 13:27h | UTC

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Addition of Neoadjuvant Nivolumab to Platinum-Based Chemotherapy in Stage III NSCLC – The ASCO Post

 

Commentary on Twitter

 


Perspective | Early-stage lung cancer: using circulating tumor DNA to get personal

26 Jun, 2023 | 00:38h | UTC

Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal – Journal of Clinical Oncology

 


Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions

26 Jun, 2023 | 00:31h | UTC

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions – CA: A Cancer Journal for Clinicians

 


Cohort Study | Stopping immunotherapy in patients that are progression-free at 2 years seems feasible in advanced NSCLC

21 Jun, 2023 | 13:19h | UTC

Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer – JAMA Oncology (link to abstract – $ for full-text)

News Release: Real-World Data Suggests Stopping Immunotherapy after Two Years is Reasonable in Patients with Advanced Lung Cancer – Penn Medicine

 

Commentary on Twitter

 


RCT | Perioperative pembrolizumab improves pathological outcomes, event-free survival in early-stage NSCLC

6 Jun, 2023 | 14:36h | UTC

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | Befotertinib tops Icotinib in NSCLC progression-free survival, but increases serious adverse events

6 Jun, 2023 | 14:13h | UTC

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)

 


RCT | Osimertinib improves overall survival in resected EGFR-mutated NSCLC, but validity of control group questioned on social media

5 Jun, 2023 | 13:46h | UTC

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter by Dr. Vinay Prasad (recommended – click to see the video)

 


RCT | Gefitinib plus chemotherapy vs. Gefitinib alone in untreated EGFR-mutant NSCLC with brain metastases

16 May, 2023 | 14:30h | UTC

Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study – JAMA Network Open

 

Commentary on Twitter

 


Clinical Trial Update | Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer

16 May, 2023 | 14:25h | UTC

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study – Journal of Clinical Oncology

Commentaries:

At 5-Year Follow-Up, Benefits of Pembrolizumab on Clinical Outcomes in Squamous NSCLC Maintained – ASCO Daily News

Addition of Pembrolizumab to Chemotherapy in First-Line Treatment of Metastatic Squamous NSCLC: 5-Year Update of KEYNOTE-407 – The ASCO Post

Original Study: Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer – New England Journal of Medicine

 


Post-pneumonectomy syndrome: a systematic review of the current evidence and treatment options

15 May, 2023 | 12:45h | UTC

Post-pneumonectomy syndrome: a systematic review of the current evidence and treatment options – Journal of Cardiothoracic Surgery

 


ASTRO/ESTRO Guideline | Treatment of oligometastatic non-small cell lung cancer

4 May, 2023 | 13:44h | UTC

Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline – Practical Radiation Oncology

News Release: ASTRO and ESTRO issue clinical guideline on local therapy for oligometastatic lung cancer – American Society for Radiation Oncology (ASTRO)

Commentary: ASTRO and ESTRO Issue New Clinical Guidelines on Local Therapy for Patients With Oligometastatic NSCLC – The ASCO Post

 

Commentary on Twitter

 


Clinical Trial Update | Adjuvant Osimertinib for resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer

4 May, 2023 | 13:33h | UTC

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial – Journal of Clinical Oncology

Original Study: Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer – New England Journal of Medicine

News Release: Trial shows significant disease-free survival for patients diagnosed with non-small cell lung cancer – Yale University

Commentary: Adjuvant Osimertinib Significantly Improves Disease-Free Survival for Patients With Resected EGFR-Mutant NSCLC – The ASCO Post

 


RCT | Endosonography with or without confirmatory mediastinoscopy for resectable lung cancer

26 Apr, 2023 | 13:56h | UTC

Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial – Journal of Clinical Oncology

 


Updated ADAURA trial results | Adjuvant Osimertinib improves disease-free survival in resected EGFR-mutated NSCLC

5 Apr, 2023 | 13:21h | UTC

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial – Journal of Clinical Oncology

News Release: Trial Shows Significant Disease-free Survival for Patients Diagnosed With Non-small Cell Lung Cancer – Yale School of Medicine

 


Expanding Organ Usage: UK study finds organs from patients with a primary brain tumor are a viable option

27 Mar, 2023 | 13:27h | UTC

Summary: A national cohort study in the UK investigated the risk of cancer transmission from deceased donors with primary brain tumors to organ recipients. The study found no cases of brain tumor transmission among 778 transplants from 282 donors with primary brain tumors, including 262 from donors with high-grade tumors. Organ transplant survival was equivalent to that in matched controls, and some organs from donors with high-grade tumors were less likely to be transplanted.

The results suggest that the risk of cancer transmission in transplants from deceased donors with primary brain tumors is lower than previously thought. Furthermore, the study indicated that donors with brain tumors provided good-quality organs with favorable risk markers and excellent transplant outcomes. Some organs from donors with high-grade tumors were underutilized, indicating a possible aversion by transplant clinicians or patients to use these organs.

These findings imply that it may be possible to safely expand organ usage from donors with primary brain tumors without negatively impacting outcomes, potentially benefiting many patients waiting for a transplant. Although this might lead to a slight rise in transplant numbers in the UK, the findings may hold particular significance for nations with stricter guidelines, such as the United States. The study’s findings can help transplant clinicians discuss the risks and benefits of accepting organ offers from such donors.

Article: Organ Transplants From Deceased Donors With Primary Brain Tumors and Risk of Cancer Transmission – JAMA Surgery

 


RCT | Sotorasib vs. docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation

20 Mar, 2023 | 13:10h | UTC

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Practice Guide | Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing

9 Mar, 2023 | 14:04h | UTC

Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide – CA: A Cancer Journal for Clinicians

 


RCT | Effects of a respiratory distress symptom intervention for lung cancer breathlessness–cough–fatigue symptom cluster

2 Mar, 2023 | 12:51h | UTC

Respiratory distress symptom intervention for non-pharmacological management of the lung cancer breathlessness–cough–fatigue symptom cluster: randomised controlled trial – BMJ Supportive & Palliative Care

 


M-A | Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer

14 Feb, 2023 | 10:34h | UTC

Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis – JNCI: Journal of the National Cancer Institute

Commentary: Predicting Outcomes in NSCLC Patients Treated With Immunotherapy or Immunochemotherapy – Cancer Therapy Advisor

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.